The link basically says(summary): Edding Group soon to be listed in Hong Kong Stock Exchange, seems to be underwritten by Morgan Stanley and Credit Suisse. Focus primarily on therapeutics and Drugs on Preventing Infection, CVD and Respiratory Diseases. 6 core products including Vascepa. Shareholders include Sequoia Capital amongst others. Revenue around 1.7BHKD. Profit 173M and 87M for 2019 and 2020 respectively